BioSpace News Archive

Novanta Inc. (Nasdaq: NOVT) (the “Company”), a trusted technology partner to medical and advanced technology equipment manufacturers, will release its second quarter 2022 results on Tuesday, August 9, 2022.

Annexon, Inc., a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, announced the closing of its private placement, resulting in gross proceeds of approximately $130 million, before deducting placement agent fees and other expenses.

Mesoblast Limited (Nasdaq:MESO; ASX:MSB), today announced that rexlemestrocel-L, its allogeneic “off-the-shelf” product candidate for the treatment of chronic heart failure (CHF) with reduced ejection fraction (HFrEF), will be highlighted in a panel discussion titled “Late-Stage Advancements in Heart Failure Therapeutics and Management”, presented by Maxim Group LLC and hosted by M-Vest, on Thursday, July 14th, 2022 at 10:00 a.m. ET.

Waters Corporation (NYSE:WAT) will hold its Q2 2022 financial results conference call live on Tuesday, August 2nd 2022 at 8:00 a.m. eastern time.

RS BioTherapeutics, whose mission is to harness its strong and thorough understanding of the endocannabinoid system (ECS) to research, develop and commercialize interventions to address chronic and acute pulmonary (lung) inflammation-based diseases, is pleased to announce positive results from its proof-of-concept study for its first investigational compound, RSBT-001.

Kelyniam Global, a maker of custom cranial implants, announced the Board Member Desiree Webb is joining the commercial team to lead Sales and Strategic Development as Vice President.

Better Therapeutics, Inc. (NASDAQ: BTTX), a prescription digital therapeutics company developing nutritional cognitive behavioral therapy (nCBT) to address the root causes of cardiometabolic diseases, today announced the publication of a manuscript detailing the study design and methodology for its pivotal clinical trial of BT-001 in adult patients with type 2 diabetes (T2D) in the medical journal, Clinical Cardiology.